НовостиBenzingaNervGen Says FDA Grants NVG-291 Breakthrough Therapy Designation For Treatment Of Chronic Traumatic Cervical Motor-Incomplete SCI NervGen Says FDA Grants NVG-291 Breakthrough Therapy Designation For Treatment Of Chronic Traumatic Cervical Motor-Incomplete SCI Benzinga 2026.11.12 12:21 (GMT+0) Открыть на Benzinga Другие новости